Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] closed the trading session at $31.03 on 2025-07-10. The day’s price range saw the stock hit a low of $29.06, while the highest price level was $33.4075.
The stocks have a year to date performance of -25.20 percent and weekly performance of -21.35 percent. The stock has been moved at -27.25 percent over the last six months. The stock has performed -16.21 percent around the most recent 30 days and changed -0.08 percent over the most recent 3-months.
If compared to the average trading volume of 1.08M shares, RARE reached to a volume of 12946002 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Ultragenyx Pharmaceutical Inc [RARE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RARE shares is $86.32 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RARE stock is a recommendation set at 1.21. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
William Blair have made an estimate for Ultragenyx Pharmaceutical Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 28, 2025. While these analysts kept the previous recommendation, Goldman raised their target price from $56 to $67. The new note on the price target was released on June 06, 2024, representing the official price target for Ultragenyx Pharmaceutical Inc stock. Previously, the target price had yet another raise to $77, while RBC Capital Mkts analysts kept a Outperform rating on RARE stock.
The Price to Book ratio for the last quarter was 20.17, with the Price to Cash per share for the same quarter was set at 5.32.
RARE stock trade performance evaluation
Ultragenyx Pharmaceutical Inc [RARE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -21.35. With this latest performance, RARE shares dropped by -16.21% in over the last four-week period, additionally sinking by -27.25% over the last 6 months – not to mention a drop of -26.23% in the past year of trading.
Ultragenyx Pharmaceutical Inc [RARE]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Ultragenyx Pharmaceutical Inc [RARE] shares currently have an operating margin of -86.94% and a Gross Margin at 79.08%. Ultragenyx Pharmaceutical Inc’s Net Margin is presently recorded at -93.04%.
Return on Equity for this stock declined to -41.97%, with Return on Assets sitting at -41.97%.
Earnings per share (EPS) analysis for Ultragenyx Pharmaceutical Inc [RARE] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RARE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ultragenyx Pharmaceutical Inc go to 62.33%.
Ultragenyx Pharmaceutical Inc [RARE]: Institutional Ownership
There are presently around $98.45%, or 101.70% of RARE stock, in the hands of institutional investors. The top three institutional holders of RARE stocks are: VANGUARD GROUP INC with ownership of 9.78 million shares, which is approximately 11.2964%. BLACKROCK INC., holding 5.6 million shares of the stock with an approximate value of $$230.3 million in RARE stocks shares; and BLACKROCK INC., currently with $$220.08 million in RARE stock with ownership which is approximately 6.1847%.
